Injectable GLP-1 Medications

Click to select Patient or Prescriber Pages Directly
       

Semaglutide is a GLP-1 antagonist that has been used in patients with type 2 diabetes control their blood sugar for many years. It is marketed by Novo Nordisk as an injection as the drug Ozempic® and as an oral tablet as Rybelsus®. The FDA recently approved a new use for the drug, allowing it to help patients battling chronic weight management. This is the same injectable drug but marketed by Novo Nordisk as Wegovy®.

Late in 2023 the Food and Drug Administration approved Zepbound® (tirzepatide) injection for chronic weight management in adults with obesity and a BMI of 30 or over with at least one weight-related condition (such as high blood pressure, type 2 diabetes or high cholesterol) for use, in addition to a reduced calorie diet and increased physical activity.

With the use of any compounded GLP-1 medications, it is strongly advised that patients strive to clean up their diets, lower their caloric intake and increase their physical activities to achieve their desired weight goals if they are using these for weight loss.

Due to strong patient requests for compounded GLP-1s, we now offer a compounded oral sublingual semaglutide. The only injectables on the market are the branded drugs that are FDA approved for use.